Meeting the information needs of drug purchasers : The evolution of formulary submission guidelinesLANGLEY, P. C.Clinical therapeutics. 1999, Vol 21, Num 4, pp 768-787, issn 0149-2918Article

The role of pharmacoeconomic guidelines for formulary approval : the Australian experienceLANGLEY, P. C.Clinical therapeutics. 1993, Vol 15, Num 6, pp 1154-1176, issn 0149-2918Article

Cost-effectiveness profiles with an expanding treatment populationLANGLEY, P. C.Clinical therapeutics. 1995, Vol 17, Num 6, pp 1207-1212, issn 0149-2918Article

Outcomes research and modeling therapeutic interventions for economic evaluationsLANGLEY, P. C.Clinical therapeutics. 1994, Vol 16, Num 3, pp 538-552, issn 0149-2918Article

The future of pharmacoeconomics : A commentaryLANGLEY, P. C.Clinical therapeutics. 1997, Vol 19, Num 4, pp 762-769, issn 0149-2918Article

Improving health care outcomes through reallocation of health care expendituresLANGLEY, P. C.Clinical therapeutics. 1997, Vol 19, Num 5, pp 1092-1100, issn 0149-2918Article

Therapy evaluation, patient distribution, and cost-outcomes ratiosLANGLEY, P. C.Clinical therapeutics. 1995, Vol 17, Num 2, pp 341-347, issn 0149-2918Article

The technology of metered-dose inhalers and treatment costs in asthma : A retrospective study of breath actuation versus traditional press-and-breathe inhalersLANGLEY, P. C.Clinical therapeutics. 1999, Vol 21, Num 1, pp 236-252, issn 0149-2918Article

Assessing the input costs of disease management programsLANGLEY, P. C.Clinical therapeutics. 1996, Vol 18, Num 6, pp 1334-1340, issn 0149-2918Conference Paper

Pharmaeconomics and the quality of decision-making by pharmacy and therapeutics committeesLANGLEY, P. C.American journal of health-system pharmacy. 1995, Vol 52, Num 14, pp S24-S26, issn 1079-2082, SUP3Article

A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgeryHAWKINS, D. W; LANGLEY, P. C; KRUEGER, K. P et al.Clinical therapeutics. 1998, Vol 20, Num 1, pp 182-195, issn 0149-2918Article

Modeling the impact of treatment options in genital warts : Patient-applied versus physician-administered therapiesLANGLEY, P. C; RICHWALD, G. A; SMITH, M. H et al.Clinical therapeutics. 1999, Vol 21, Num 12, pp 2143-2155, issn 0149-2918Article

A review of cost-of-illness studies on obesityKORTT, M. A; LANGLEY, P. C; COX, E. R et al.Clinical therapeutics. 1998, Vol 20, Num 4, pp 772-779, issn 0149-2918Article

Disease management programsARMSTRONG, E. P; LANGLEY, P. C.American journal of health-system pharmacy. 1996, Vol 53, Num 1, pp 53-58, issn 1079-2082Article

A cost-benefit analysis of four hormonal contraceptive methodsORTMEIER, B. G; SAUER, K. A; LANGLEY, P. C et al.Clinical therapeutics. 1994, Vol 16, Num 4, pp 707-713, issn 0149-2918Article

Risperidone versus haloperidol : II. cost-effectivenessDAVIES, A; LANGLEY, P. C; KEKS, N. A et al.Clinical therapeutics. 1998, Vol 20, Num 1, pp 196-213, issn 0149-2918Article

Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacementHAWKINS, D. W; LANGLEY, P. C; KRUEGER, K. P et al.American journal of health-system pharmacy. 1997, Vol 54, Num 10, pp 1185-1190, issn 1079-2082Article

Treatment costs, equilibrium, and the allocation of patients to therapy alternativesLANGLEY, P. C; BHATTACHARYYA, S. K.Clinical therapeutics. 1997, Vol 19, Num 4, pp 830-836, issn 0149-2918Article

Cost-effectiveness of regional poison control centersHARRISON, D. L; DRAUGALIS, J. R; SLACK, M. K et al.Archives of internal medicine (1960). 1996, Vol 156, Num 22, pp 2601-2608, issn 0003-9926Article